VANCOUVER, British Columbia – Qu Biologics Inc. announced in a press release that the US Patent and Trademark Office has issued US Patent No. 8,980,279 relating to the use of immunotherapies derived from components of E. coli to treat Crohn’s disease.
The allowed claims of the patent, which issued on March 17, 2015, cover the use of E. colicomponents as SSIs to stimulate an immune response to treat Crohn’s disease. This latest patent builds on Qu Biologics’ patent portfolio covering SSI treatment of a range of inflammatory disorders and cancers.
Dr. Hal Gunn, Chief Executive Officer of Qu Biologics, commented, “We are very pleased to have been granted this important US patent that covers our novel Crohn’s treatment in clinical use in our randomized, placebo-controlled clinical trial.” Dr. Gunn added, “Our SSIs aim to address the underlying immunological causes of many chronic inflammatory diseases, representing a novel treatment approach that restores the body’s own immune response. We will continue to further strengthen our patent position as we advance our clinical trials in inflammatory bowel disease.”
Qu Biologics’ Site Specific Immunomodulators (SSIs) are derived from components of bacteria and are designed to stimulate the body’s immune system to treat cancer and other immune-related diseases, such as Crohn’s disease and ulcerative colitis. Qu Biologics has developed multiple SSIs, each of which targets a specific organ/tissue.